Norgine Gains Australia Approval for PEDMARQSI®
AMSTERDAM, The Netherlands – May 6, 2026 Norgine has announced that the Australian Therapeutic Goods Administration (TGA) has granted...
Alzheimer’s Disease ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody NSCLC Oncology oncology innovation oncology research Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
AMSTERDAM, The Netherlands – May 6, 2026 Norgine has announced that the Australian Therapeutic Goods Administration (TGA) has granted...
Singapore | May 4, 2026 Specialised Therapeutics has announced that NIKTIMVO® (axatilimab) has received regulatory approval from the Therapeutic...
VALENCIA, Calif., April 29, 2026 AVITA Medical, Inc. has announced that its next-generation wound care platform RECELL GO® has...
CAMBRIDGE, Mass., USA, March 31, 2026 Alltrna has received regulatory approval to initiate the first-in-human clinical trial of AP003,...
